Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 40 clinical trials
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US Spanish  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

  • 268 views
  • 26 Feb, 2021
  • 16 locations
featured
TRANSCEND - Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - TRANSCEND-CLL-004 - US  

Phase 2 single-arm, multi-cohort study to determine the efficacy and safety of JCAR017 (autologous T cells expressing anti-CD19 chimeric antigen receptor) in adult subjects with aggressive B-NHL (diffuse large B-cell lymphoma (DLBCL) NOS [de novo or transformed follicular lymphoma (tFL)], double/triple-hit lymphoma [DHL/THL], follicular lymphoma Grade 3B [FL3B], primary central …

  • 1875 views
  • 04 Mar, 2021
  • 15 locations
The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma

This is an open-label, Phase 1/2 study designed to characterize the safety, tolerability, Pharmacokinetics(PK), and preliminary antitumor activity of AVM0703 administered as a single intravenous (IV) infusion to patients with lymphoid malignancies.

  • 0 views
  • 28 Jan, 2021
  • 3 locations
Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma

chimeric antigen receptor) (DLBCL NOS [de novo or tFL], follicular lymphoma Grade 3B [FL3B], high grade B-cell Lymphoma [HGBL] and primary central nervous system lymphoma [PCNSL]).

rituximab
follicular lymphoma
diffuse large b-cell lymphoma
b-cell lymphoma
gilbert's syndrome
  • 191 views
  • 27 Jan, 2021
  • 29 locations
GEN3013 Trial in Patients With Relapsed Progressive or Refractory B-Cell Lymphoma

The trial is an open-label, multi-center safety trial of epcoritamab GEN3013 (DuoBody-CD3xCD20). The trial consists of two parts: a dose escalation part phase 1, first-in-human (FIH) and an expansion part phase 2a.

rituximab
ct scan
b-cell lymphoma
combination chemotherapy
pet/ct scan
  • 316 views
  • 24 Feb, 2021
  • 99 locations
R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)

with High-Grade B-cell Lymphoma Double-hit and High-Grade B-cell Lymphoma Not Otherwise Specified.

cell transplantation
b-cell lymphoma
diffuse large b-cell lymphoma
  • 34 views
  • 22 Jan, 2021
  • 1 location
Testing the Addition of a New Anti-cancer Drug Venetoclax to Usual Chemotherapy for High Grade B-cell Lymphomas

This phase II/III trial tests whether it is possible to decrease the chance of high-grade B-cell lymphomas returning or getting worse by adding a new drug, venetoclax to the usual combination of

venetoclax
cancer
cyclophosphamide
da-epoch
rituximab
  • 168 views
  • 05 Mar, 2021
  • 511 locations
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

cancer
b-cell lymphoma
bone marrow procedure
bone marrow transplant
measurable disease
  • 38 views
  • 26 Jan, 2021
  • 11 locations
FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL

transplant (auto-HSCT) for diffuse large or high-grade B cell lymphoma.

rituximab
remission
b-cell lymphoma
  • 0 views
  • 26 Jan, 2021
  • 2 locations
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma

This phase II trial studies how well polatuzumab vedotin and combination chemotherapy work in treating patients with previously untreated double or triple hit lymphoma. Polatuzumab vedotin is a monoclonal antibody that works by binding with cancer cells and releasing another chemotherapy drug, called monomethyl auristatin E, into the cell causing …

cancer
cyclophosphamide
monoclonal antibodies
rituximab
platelet count
  • 0 views
  • 24 Jan, 2021